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Abstract
Background: Recurrence risks for familial congenital anomalies in successive pregnancies are known, but this
information for major structural anomalies is lacking. We estimated the absolute and relative risks of recurrent
congenital anomaly in the second pregnancy for women with a history of a congenital anomaly in the first
pregnancy, for all major anomaly groups and subtypes.
Methods: Population-based register data on 18,605 singleton pregnancies affected by major congenital anomaly
occurring in 872,493 singleton stillbirths, live births and terminations of pregnancy for fetal anomaly were
obtained from the Northern Congenital Abnormality Survey, North of England, UK, for 1985–2010. Absolute risks
(ARs) and relative risks (RRs) for recurrent congenital anomaly (overall, from a similar group, from a dissimilar
group) in the second pregnancy were estimated by history of congenital anomaly (overall, by group, by subtype)
in the first pregnancy.
Results: The estimated prevalences of congenital anomaly in first and second pregnancies were 275 (95% CI
270–281) and 163 (95% CI 159–168) per 10,000 respectively. For women whose first pregnancy was affected by
congenital anomaly, the AR of recurrent congenital anomaly in the second pregnancy was 408 (95% CI 365–456) per
10,000, 2.5 (95% CI 2.3–2.8, P < 0.0001) times higher than for those with unaffected first pregnancies. For similar
anomalies, the recurrence risk was considerably elevated (RR = 23.8, 95% CI 19.6–27.9, P < 0.0001), while for dissimilar
anomalies the increase was more modest (RR = 1.4, 95% CI 1.2–1.6, P = 0.001), although the ARs for both were 2%.
Conclusions: Absolute recurrence risks varied between 1 in 20 and 1 in 30 for most major anomaly groups. At pre-
conception and antenatal counselling, women whose first pregnancy was affected by a congenital anomaly and who
are planning a further pregnancy may find it reassuring that, despite high relative risks, the absolute recurrence risk is
relatively low.
Keywords: Congenital anomalies, Northern Congenital Abnormality Survey (NorCAS), Recurrence, Prenatal counselling,
Siblings
Background
Congenital anomalies are a leading cause of morbidity
and mortality in early life. Affecting 1–6% of viable preg-
nancies worldwide [1–4], they cause around 3.3 million
annual deaths in children aged under 5 years [3], includ-
ing a quarter of all infant deaths in high income
countries [5–7]. For long-term survivors, the prognosis
varies greatly between conditions and settings, but
many experience significant physical and/or psycho-
logical impairments, resulting in sustained health and
social care needs at considerable cost [8].
Although the number of children born with the most
severe congenital anomalies has reduced with improve-
ments in the availability and sensitivity of prenatal
screening [1, 9], a congenital anomaly diagnosis, and the
subsequent discussion around termination of pregnancy,
is associated with significant emotional distress [10].
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Families with a familial condition or who have previously
lost a child or pregnancy to a congenital anomaly are
hence often particularly concerned about the risk of re-
currence in future pregnancies [11].
Genetic counselling provides guidance and support
for those families who are affected by conditions with
known inheritance patterns [12, 13], but since the aeti-
ology of most congenital anomalies is multifactorial or
unknown [14], there is a lack of information concern-
ing the recurrence risks for most anomaly groups and
subtypes. The best available data come from three
population-based studies published in the 1990s, all of
which found that previous congenital anomaly was as-
sociated with around twice the risk in a subsequent
pregnancy, including five to twelve times the risk for
similar anomalies [15–17]. Unfortunately, modest sam-
ple sizes, the use of outdated and unclear classification
schemes (e.g. including a high proportion of minor
anomalies) and a lack of detail for specific congenital
anomaly subtypes limit their value for current pre-
conception and prenatal counselling.
This study used data from the UK’s longest-running
population-based register of congenital anomalies to
estimate the absolute and relative risks of recurrent
congenital anomaly in the second pregnancies of
mothers with a history of congenital anomaly in their
first pregnancy.
Methods
Study population
The Northern Congenital Abnormality Survey (NorCAS)
records details of all cases of congenital anomaly
whether arising in late miscarriage (20–23 weeks’ gesta-
tion), termination of pregnancy for fetal anomaly
(TOPFA) following prenatal diagnosis (any gestation),
stillbirth (≥24 weeks’ gestation) or live birth to mothers
resident in the North of England (population: ≈3 million;
births: ≈32,000 per year). The North of England is char-
acterised by a relatively stable population with low levels
of both inward and outward migration, and a relatively
low percentage (about 5%) of the population is from mi-
nority ethnic groups [18]. Data on all major congenital
anomalies occurring in singleton pregnancies to women
resident in the region from 1 January 1985 to 31 Decem-
ber 2010, regardless of place of delivery, were obtained
from the NorCAS. Cases are notified from multiple
sources, including antenatal ultrasound, fetal medicine
departments, cytogenetic laboratories, the regional car-
diology centre, pathology departments and paediatric
surgery, and are included when first diagnosed at any
age up to 12 years (16 years for cases born during
1985–2001). The NorCAS, as a member of the Euro-
pean Surveillance of Congenital Anomalies (EUROCAT
[19]), follows the EUROCAT definitions, classification
and inclusion criteria. Data were cross-validated with
the National Congenital Anomaly System (NCAS) on
an annual basis. Data on all regional births (stillbirths
and live births) were provided by the UK Office for
National Statistics, and TOPFAs from the NorCAS
were added to the denominator.
Inclusion and exclusion criteria
Figure 1 shows the derivation of the study sample,
which comprises all singleton first and second pregnan-
cies affected by major congenital anomaly notified to
the NorCAS during the study period. Cases arising in
spontaneous miscarriage before 20 weeks, in subse-
quent (parity ≥2) pregnancies, that did not satisfy the
EUROCAT definition of a major congenital anomaly [20]
or that formed part of a known teratogenic syndrome (e.g.
due to valproate use or primary cytomegalovirus infec-
tion) were excluded. Multiple pregnancies were also ex-
cluded due to higher congenital anomaly prevalence
[21, 22], particularly for monochorionic twins [22].
Identification of recurrent cases
Mothers with recurrent pregnancies affected by congenital
anomaly were identified from the NorCAS maternal index
number, a unique number given to each new mother
when first recorded on the database. The mother’s
National Health Service (NHS) number (complete from
2003 onwards), name, date of birth, postcode of residence
and hospital of delivery, as well as the baby’s details were
used to cross-validate all recurrent pregnancies and iden-
tify duplicate records.
Definitions and classification of congenital anomalies
The NorCAS records text descriptions and WHO ICD-
10 [23] codes for up to six individual congenital anomal-
ies per case. These were categorised into group (the
organ system affected, e.g. ‘cardiovascular’), subtype (the
specific condition, e.g. ‘coarctation of the aorta’) and
syndrome (e.g. ‘DiGeorge syndrome’) based on EURO-
CAT guidelines [24, 25]. Cases with more than one
ICD code were assigned a primary diagnosis using a hier-
archical approach [26] with the highest allocated from: (1)
chromosomal syndromes (anomalies of chromosomal
number or structure, e.g. ‘Down syndrome’); (2) genetic
syndromes (patterns of anomalies arising from a single
gene, e.g. ‘DiGeorge syndrome’) [24]; (3) skeletal dyspla-
sias (syndromes of skeletal development, e.g. ‘osteogenesis
imperfecta’ [24]); (4) other genetic anomalies (resulting
from microdeletions or mutations, e.g. ‘neurofibroma-
tosis’); or (5) other syndromes of non-genetic origin
(recognised patterns of anomalies, with or without a
known cause, e.g. ‘Noonan syndrome’) [24].
Isolated cases were allocated to their primary anomaly
group and subtype. Cases with two or more structural
Glinianaia et al. BMC Medicine  (2017) 15:20 Page 2 of 14
anomalies were reviewed to identify a primary group or
subtype or to assign a diagnosis of multiple anomalies
(two or more unrelated structural anomalies across sep-
arate organs). More details of the classification principles
are described elsewhere [26].
Congenital anomalies occurring in successive pregnan-
cies of the same woman were considered ‘similar’ if they
belonged to the same group (e.g. cardiovascular) or the
same syndromic group (e.g. chromosomal syndromes),
regardless of the specific subtypes, and ‘dissimilar’ if they
belonged to different groups.
Statistical analysis
The total number of first and second singleton births in
the background population of the North of England
during 1985–2010 (n = 872,493) was estimated from the
mean of the percentage of first and second births in
England and Wales during 1990 and 2000 [27]. Parity
information for pregnancies affected by congenital
anomaly, complete for around half the sample, was sup-
plemented by multiple imputation. Ten datasets were
generated via multivariate imputation by chained equa-
tions using maternal age, year of delivery, socioeco-
nomic position (SEP, estimated from the 2007 index of
multiple deprivation derived from the mother’s residen-
tial postcode at delivery) and birth weight. All statistics
and standard errors, from which 95% confidence inter-
vals (CIs) were derived, were determined independently
within each imputed dataset and combined using
Rubin’s rule to generate summary standard errors. The
number of second pregnancies for women whose first
pregnancy was affected by a congenital anomaly was
predicted from the mean parity progression ratios for
England and Wales during 1990 and 2000 [27].
The prevalence of congenital anomaly (overall, by
group, by subtype) for first and second pregnancies was
calculated as the estimated number of affected pregnan-
cies per 10,000 (live births, stillbirths and TOPFAs). 95%
CIs for prevalence proportions were approximated from
the summary standard errors by logit transformation
[28]. The prevalence — henceforth described as the ab-
solute risk (AR) — of recurrent congenital anomaly (any,
similar, dissimilar) in the second pregnancy was deter-
mined as the ratio of recurrent cases divided by the total
estimated second pregnancies in those with a first preg-
nancy affected by congenital anomaly (any, by group, by
subtype). Relative risks (RRs) of recurrent congenital
anomaly (any, similar, dissimilar) were estimated by
Fig. 1 Details and derivation of the study population and sample. aEstimated from the mean percentage of first and second births in England
and Wales during 1990 and 2000 [27]. bEstimated from the mean parity progression ratios for England and Wales during 1990 and 2000 [27]
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comparing the prevalence in those whose first pregnancy
was affected by congenital anomaly (overall, by group,
by subtype) to the prevalence in those with no record of
congenital anomaly in their first pregnancy. To minimise
any potential bias arising from the incomplete capture of
linked first and second pregnancies at the beginning and
end of the study period, we restricted the window for ex-
posure, i.e. during which the first pregnancy must occur,
to 1985–2008 and the window for outcome, i.e. during
which the second pregnancy must occur, to 1987–2010.
This corresponds with the modal inter-pregnancy inter-
val among recurrent pregnancies (2 years) in our sample
and provides a minimum of one complete year between
deliveries. Only those groups and subtypes with at least
three recurrent pregnancies are reported in the tables.
Summary ARs for similar and dissimilar anomalies
were estimated as the weighted average of the ARs of
similar (or dissimilar) anomalies across all groups, with
weights equal to the number ‘exposed’ to a similar (or
dissimilar) anomaly in the first pregnancy. The summary
RRs for similar and dissimilar anomalies were estimated
by non-linear combination of the ARs, with CIs approxi-
mated using the delta method. The effect of maternal
age and SEP (analysed as tertiles) in the first pregnancy
on the odds of congenital anomaly in the second preg-
nancy was examined by logistic regression, with non-
recurrent cases weighted by the aforementioned parity
progression ratios.
Two sensitivity analyses were performed. Firstly, a
‘complete case’ analysis of the AR and RR of recur-
rent congenital anomaly in the second pregnancy was
carried out in the subsample of pregnancies with
complete parity. Simple inverse probability weights
were used to correct for differences in the proportion
of missing data between recurrent and non-recurrent
second pregnancies. Secondly, we examined the po-
tential impact of temporal changes in the prevalence
of congenital anomalies on the RR of recurrence by
calculating and comparing the RRs during the first
and the second half of the study period (1987–1998
and 1999–2010 respectively).
Analyses were performed using Stata version 13.1
(Statacorp, College Station, TX, USA). P values are pre-
sented for transparency, but no formal hypothesis tests
were performed.
Results
A total of 872,493 singleton stillbirths, live births and
TOPFAs occurred during the 26 years, including 18,605
affected by major congenital anomaly, a prevalence of
213 (95% CI 210–216) per 10,000 births and TOPFAs.
Of these, an estimated 9999 cases occurred in a first
pregnancy from a predicted 362,952 first births and
TOPFAs, a prevalence of 275 (95% CI 270–281) per
10,000, and an estimated 4890 cases occurred in a sec-
ond pregnancy from a predicted 299,697 second births
and TOPFAs, a prevalence of 163 (95% CI 159–168) per
10,000 (Fig. 1).
Table 1 shows the prevalence of congenital anomaly,
by group and subtype, in the first and the second
pregnancy individually. The estimated total prevalence
of congenital anomaly was 40.8% lower (95% CI 38.7–
42.7, P < 0.0001) among second pregnancies than first
pregnancies, but there were noticeable differences in
the magnitude of decrease between anomaly groups
(P < 0.0001).
From the 9231 women whose first pregnancies were
affected by congenital anomaly during 1985–2008, 301
had second pregnancies affected by congenital anomaly,
and a further 7362 were predicted to have a second
pregnancy unaffected by congenital anomaly during
1987–2010 (Fig. 1). The AR of recurrent congenital
anomaly in the second pregnancy was 408 (95% CI
365–456) per 10,000, an RR of 2.52 (95% CI 2.25–2.83,
P < 0.0001) times greater than that among women
whose first pregnancies were unaffected by congenital
anomaly (Table 2). This comprised a summary AR of
204 (95% CI 169–239) per 10,000 for a similar anomaly,
an RR of 23.8 (95% CI 19.6–27.9, P < 0.0001) times
greater than that among women whose first pregnan-
cies were unaffected, and a summary AR of 204 (95%
CI 169–239) for a dissimilar anomaly, an RR of 1.40
(95% CI 1.16–1.64, P = 0.001) times greater than that
among those whose first pregnancies were unaffected
(Table 3). The RRs of a similar anomaly were substan-
tially elevated for both syndromic (RR = 33.6, 95% CI
24.4–48.9, P < 0.0001) and isolated (RR = 19.9, 95% CI
15.5–24.4, P < 0.0001) anomalies (Table 3). For dissimi-
lar anomalies, the RR was higher for syndromic anom-
alies (RR = 1.74, 95% CI 1.24–2.23, P = 0.004) than
isolated anomalies, where the effect was very modest
(RR = 1.27, 95% CI 1.00–1.55, P = 0.05).
Table 3 also shows the extent of heterogeneity be-
tween anomaly groups in the RRs of recurrence for
both similar (P < 0.0001) and dissimilar (P = 0.025)
anomalies. For similar anomalies, the RRs were greatly
elevated for all anomaly groups compared to women
with unaffected first pregnancies. For dissimilar anom-
alies, most potential associations were too small —
given the study sample size — to distinguish from
unity, except for musculoskeletal anomalies, genetic
syndromes and multiple congenital anomalies (Table 3).
Despite high RRs for similar anomalies, the ARs were
relatively low (Tables 3 and 4). Overall, for most major
anomaly groups, absolute recurrence risks varied be-
tween 1 in 20 and 1 in 30, except for very rare genetic
syndromes and other genetic anomalies for which the
risks were higher (Table 4).
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Table 1 Prevalence of congenital anomaly in the first and second pregnancies and relative reduction in prevalence, by group
and subtype
Congenital anomaly group/subtype First pregnancies Second pregnancies Relative reduction in prevalence
N Prevalence per 10,000
(95% CI)
N Prevalence per 10,000
(95% CI)
% (95% CI) P value
Isolated anomalies 7162 197.3 (192.8-201.9) 3360 112.1 (108.4-116.0) 43.2 (40.8-45.4) <0.0001
Nervous system 989 27.2 (25.6-29.0) 467 15.6 (14.2-17.0) 42.8 (36.2-48.8) <0.0001
Neural tube defects 649 17.9 (16.6-19.3) 309 10.3 (9.2-11.5) 42.3 (34.0-49.6) <0.0001
Anencephaly 278 7.7 (6.8-8.6) 130 4.3 (3.7-5.2) 43.4 (30.3-54.0) <0.0001
Encephalocele 47 1.3 (1.0-1.7) 27 0.9 (0.6-1.3) 30.4 (-11.7-56.7) 0.14
Spina bifida 324 8.9 (8.0-10.0) 152 5.1 (4.3-6.0) 43.2 (31.1-53.1) <0.0001
Hydrocephalus 127 3.5 (2.9-4.1) 53 1.8 (1.4-2.3) 49.5 (30.4-63.3) 0.0001
Microcephaly 66 1.8 (1.4-2.3) 34 1.1 (0.8-1.6) 37.6 (5.6-58.7) 0.03
Eye 81 2.2 (1.8-2.8) 35 1.2 (0.8-1.6) 47.7 (22.2-64.8) 0.002
Ear-face-neck 13 0.4 (0.2-0.6) 5 0.2 (0.1-0.4) 53.4 (-30.7-83.4) 0.15
Cardiovascular 3085 85.0 (82.1-88) 1619 54.0 (51.5-56.7) 36.4 (32.5-40.1) <0.0001
Transposition of the great vessels 158 4.4 (3.7-5.1) 76 2.5 (2.0-3.2) 41.7 (23.4-55.7) 0.0002
Single ventricle 22 0.6 (0.4-0.9) 11 0.4 (0.2-0.7) 39.4 (-24.9-70.6) 0.18
Ventricular septal defect (VSD) 1300 35.8 (33.9-37.8) 672 22.4 (20.8-24.2) 37.4 (31.3-43.0) <0.0001
Atrial septal defect (ASD) 221 6.1 (5.3-6.9) 121 4.0 (3.4-4.8) 33.7 (17.2-46.9) 0.0005
Pulmonary valve stenosis 266 7.3 (6.5-8.3) 134 4.5 (3.8-5.3) 39.0 (24.9-50.4) <0.0001
Aortic valve atresia/stenosis 133 3.7 (3.1-4.4) 73 2.4 (1.9-3.1) 33.5 (11.6-50.0) 0.006
Hypoplastic left heart 69 1.9 (1.5-2.4) 48 1.6 (1.2-2.1) 15.8 (-21.8-41.7) 0.37
Coarctation of the aorta 170 4.7 (4.0-5.4) 87 2.9 (2.3-3.6) 38.0 (19.8-52.1) 0.0004
Respiratory 70 1.9 (1.5-2.4) 36 1.2 (0.9-1.7) 37.7 (6.9-58.3) 0.02
Orofacial clefts 533 14.7 (13.5-16.0) 189 6.3 (5.5-7.3) 57.1 (49.3-63.6) <0.0001
Cleft lip 141 3.9 (3.3-4.6) 51 1.7 (1.3-2.2) 56.2 (39.7-68.2) <0.0001
Cleft lip and palate 206 5.7 (4.9-6.5) 71 2.4 (1.9-3.0) 58.3 (45.3-68.1) <0.0001
Cleft palate 186 5.1 (4.4-5.9) 67 2.2 (1.8-2.9) 56.4 (42.3-67.0) <0.0001
Digestive system 496 13.7 (12.5-14.9) 224 7.5 (6.6-8.5) 45.3 (36.0-53.3) <0.0001
Oesophageal atresia 74 2.0 (1.6-2.6) 27 0.9 (0.6-1.3) 55.8 (31.3-71.6) 0.0004
Hirschsprung disease 60 1.7 (1.3-2.1) 24 0.8 (0.5-1.2) 51.6 (22.2-69.8) 0.003
Diaphragmatic hernia 111 3.1 (2.5-3.7) 57 1.9 (1.5-2.5) 37.8 (14.4-54.8) 0.004
Abdominal wall 310 8.5 (7.6-9.5) 90 3.0 (2.4-3.7) 64.8 (55.5-72.2) <0.0001
Gastroschisis 243 6.7 (5.9-7.6) 65 2.2 (1.7-2.7) 67.6 (57.4-75.4) <0.0001
Urinary 1035 28.5 (26.8-30.3) 506 16.9 (15.5-18.4) 40.8 (34.2-46.8) <0.0001
Cystic kidney disease 199 5.5 (4.8-6.3) 103 3.4 (2.8-4.2) 37.3 (20.5-50.6) 0.0002
Genital 91 2.5 (2.0-3.1) 39 1.3 (0.9-1.8) 48.1 (24.5-64.3) 0.0009
Limb 317 8.7 (7.8-9.8) 85 2.8 (2.3-3.5) 67.5 (58.7-74.4) <0.0001
Polydactyly 38 1.1 (0.8-1.5) 16 0.5 (0.3-0.9) 49.0 (8.6-71.6) 0.03
Musculoskeletal 60 1.7 (1.3-2.1) 23 0.8 (0.5-1.2) 53.6 (24.9-71.3) 0.002
Craniosynostosis 34 0.9 (0.7-1.3) 11 0.4 (0.2-0.7) 60.8 (22.7-80.1) 0.008
Others 81 2.2 (1.8-2.8) 38 1.3 (0.9-1.7) 43.2 (16.5-61.4) 0.005
Cystic hygroma 60 1.7 (1.3-2.1) 25 0.8 (0.6-1.2) 49.5 (19.5-68.4) 0.005
Syndromic anomalies 2837 78.2 (75.4-81.1) 1530 51.1 (48.6-53.7) 34.7 (30.5-38.6) <0.0001
Chromosomal syndromes 1488 41.0 (39.0-43.1) 914 30.5 (28.6-32.5) 25.6 (19.2-31.5) <0.0001
Down syndrome 741 20.4 (19.0-21.9) 450 15.0 (13.7-16.5) 26.5 (17.3-34.6) <0.0001
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The odds of recurrence were higher in women with
more deprived SEPs (odds ratio, OR = 1.48, 95% CI 1.04–
2.10, P = 0.03, for most vs least deprived tertile) and de-
clined with increasing maternal age at delivery (OR = 0.95,
95% CI 0.92–0.98, P < 0.0001 per year increase). However,
maternal age and SEP were highly correlated, and when
both were examined concurrently, the effect of SEP was
attenuated (SEP: adjusted OR, aOR, for most vs least de-
prived tertile = 1.18, 95% CI 0.82–1.72, P = 0.37; maternal
age: aOR, per year = 0.95, 95% CI 0.93–0.98, P = 0.001).
When the analysis was performed in the subsample of
pregnancies with complete parity, the AR of recurrent
congenital anomaly was 419 per 10,000 (95% CI 354–
492), and the RR was 2.45 (95% CI 2.09–2.88, both
within ± 3% of the estimates derived using multiple im-
putation (AR = 408 per 10,000 (95% CI 365–456) and
RR = 2.52 (95% CI 2.25–2.83) respectively).
There was no evidence that the RR of recurrence had
changed over the study period, with similar RRs of 2.46
(95% CI 2.06–2.94) during 1987–1998 and 2.54 (95% CI
2.18–2.96) during 1999–2010 (P = 0.89).
Discussion
Using population-based register data, we found that his-
tory of congenital anomaly in the first pregnancy was as-
sociated with a 2.5-fold risk of recurrent anomaly in the
second pregnancy despite lower overall prevalence of a
congenital anomaly in second pregnancies compared
with first pregnancies. For similar anomalies, the recur-
rence risk was nearly 24 times higher, while for dissimilar
anomalies, the increase was considerably more modest
(1.4-fold). For similar anomalies, much higher recurrence
risks were observed for both isolated (20-fold) and syn-
dromic (34-fold) groups of congenital anomalies. For dis-
similar anomalies, the increased risk of recurrence was
much lower for both isolated (1.3-fold) and syndromic
(1.7-fold) anomalies. Absolute recurrence risks varied be-
tween 1 in 20 and 1 in 30 for most major anomaly groups.
Women from the most deprived areas experienced nearly
1.5 times higher odds of recurrence than those from the
least deprived areas, although this was partly explained by
differences in the maternal age distributions.
This is the first study to estimate the absolute and
relative recurrence risks of major congenital anomalies
in siblings using population-based data derived from a
high-quality congenital anomaly register, which employs
consistent, internationally approved and clinically mean-
ingful definition, classification and inclusion criteria.
The NorCAS receives information, regardless of preg-
nancy outcome, from multiple sources up to 12 years
after birth, using a well-established network of local cli-
nicians, and thereby assures high case ascertainment.
This study has some limitations. Despite being the lar-
gest study of its kind, the absolute numbers of recurrent
anomalies were low. Our estimates are thus relatively
uncertain for some rare groups and subtypes, while
Table 1 Prevalence of congenital anomaly in the first and second pregnancies and relative reduction in prevalence, by group
and subtype (Continued)
Edward syndrome 134 3.7 (3.1-4.4) 109 3.7 (3.0-4.4) 1.5 (-26.8-23.5) 0.91
Klinefelter syndrome 37 1.0 (0.7-1.4) 20 0.7 (0.4-1.1) 34.5 (-12.8-62.0) 0.13
Turner syndrome 138 3.8 (3.2-4.5) 64 2.1 (1.7-2.7) 43.8 (24.5-58.2) 0.0002
Genetic syndromes and microdeletions 433 11.9 (10.9-13.1) 213 7.1 (6.2-8.1) 40.4 (29.8-49.4) <0.0001
DiGeorge syndrome 83 2.3 (1.9-2.8) 33 1.1 (0.8-1.5) 51.8 (27.9-67.8) 0.0006
Stickler syndrome 9 0.2 (0.1-0.5) 6 0.2 (0.1-0.4) 19.3 (-126.8-71.3) 0.69
Skeletal dysplasias 106 2.9 (2.4-3.5) 57 1.9 (1.5-2.5) 34.9 (10.1-52.8) 0.010
Osteogenesis imperfecta (type II) 38 1.0 (0.8-1.4) 24 0.8 (0.5-1.2) 23.5 (-27.5-54.1) 0.31
Other syndromes, sequences, etc. 296 8.2 (7.3-9.2) 131 4.4 (3.7-5.2) 46.4 (34.2-56.4) <0.0001
Laterality disturbance syndromesa 40 1.1 (0.8-1.5) 17 0.6 (0.3-0.9) 48.5 (9.2-70.8) 0.02
Noonan syndrome 17 0.5 (0.3-0.8) 9 0.3 (0.1-0.6) 35.9 (-43.8-71.4) 0.28
Other genetic anomalies 54 1.5 (1.1-1.9) 25 0.8 (0.6-1.2) 43.9 (9.9-65.1) 0.02
Ichthyosis 22 0.6 (0.4-0.9) 7 0.2 (0.1-0.5) 61.5 (9.8-83.5) 0.03
Neurofibromatosis 11 0.3 (0.2-0.6) 6 0.2 (0.1-0.4) 33.9 (-78.6-75.6) 0.42
Multiple congenital anomalies 461 12.7 (11.6-13.9) 197 6.6 (5.7-7.5) 48.2 (38.9-56.2) <0.0001
Any congenital anomaly 9999 275.5 (270.2-280.9) 4890 163.2 (158.7-167.8) 40.8 (38.7-42.7) <0.0001
Congenital anomaly groups (e.g. nervous system) and combined groups (i.e. isolated anomalies, syndromic anomalies and any congenital anomaly) are presented
in bold text, while congenital anomaly subtypes within the groups are presented in regular text
Counts, prevalence proportions and relative reductions are the mean across ten multiply imputed datasets
Confidence intervals were estimated using a logit transformation from the summary standard errors, which were combined using Rubin’s rule
Congenital anomaly groups and subtypes are classified in accordance with EUROCAT guidelines [24, 25]
aIncludes Ivemark syndrome, left atrial isomerism and situs inversus
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Table 2 Absolute and relative risk of recurrent congenital anomaly (of any group) in the second pregnancy, by congenital anomaly
group/subtype in the first pregnancy
Congenital anomaly group/subtype in
the first pregnancy
Estimated second
pregnanciesb
Cases Absolute risk per
10,000 (95% CI)
Relative risk (95% CI) P value
Isolated anomalies 5289 190 357 (310-645) 2.17 (1.88-2.51) <0.0001
Nervous system 744 31 403 (283-571) 2.40 (1.69-3.42) <0.0001
Neural tube defects 482 16 332 (204-535) 1.97 (1.22-3.20) 0.007
Anencephaly 207 8 387 (193-761) 2.30 (1.15-4.57) 0.02
Encephalocele 34 2
Spina bifida 241 6 249 (112-543) 1.48 (0.67-3.26) 0.34
Hydrocephalus 98 5 510 (213-1170) 3.03 (1.29-7.13) 0.01
Microcephaly 52 5 968 (402-2151) 5.74 (2.47-13.36) 0.0001
Eye 63 3 481 (155-1395) 2.85 (0.94-8.65) 0.07
Ear-face-neck 11 1
Cardiovascular 2282 79 346 (278-431) 2.07 (1.66-2.58) <0.0001
Transposition of the great vessels 116 2
Single ventricle 17 2
Ventricular septal defect (VSD) 966 38 394 (287-538) 2.35 (1.71-3.22) <0.0001
Atrial septal defect (ASD) 165 8 487 (244-948) 2.89 (1.46-5.72) 0.003
Pulmonary valve stenosis 198 4 202 (76-531) 1.20 (0.45-3.19) 0.72
Aortic valve atresia/stenosis 100 3 301 (96-901) 1.79 (0.58-5.48) 0.31
Hypoplastic left heart 48 2
Coarctation of the aorta 122 4 329 (123-854) 1.95 (0.74-5.17) 0.18
Respiratory 50 1
Orofacial clefts 398 14 352 (209-586) 2.09 (1.25-3.50) 0.006
Cleft lip 103 4 388 (146-991) 2.30 (0.88-6.04) 0.01
Cleft lip and palate 154 6 390 (176-843) 2.32 (1.06-5.09) 0.04
Cleft palate 142 5 352 (147-820) 2.09 (0.88-4.96) 0.01
Digestive system 371 12 324 (185-562) 1.93 (1.10-3.37) 0.02
Oesophageal atresia 53 2
Hirschsprung disease 45 2
Diaphragmatic hernia 79 5 634 (266-1440) 3.77 (1.61-8.83) 0.003
Abdominal wall 218 3 138 (45-419) 0.82 (0.27-2.52) 0.73
Gastroschisis 172 3 174 (56-527) 1.03 (0.34-3.18) 0.96
Urinary 751 34 453 (325-628) 2.70 (1.94-3.76) <0.0001
Cystic kidney disease 145 8 550 (277-1063) 3.27 (1.66-6.42) 0.001
Genital 50 1
Limb 244 5 205 (86-483) 1.22 (0.51-2.90) 0.65
Polydactyly 27 2
Musculoskeletal 47 4 858 (322-2094) 5.09 (1.97-13.15) 0.001
Craniosynostosis 27 2
Others 61 2
Cystic hygroma 45 2
Syndromic anomalies 2072 111 538 (448-645) 3.25 (2.70-3.91) <0.0001
Chromosomal syndromes 1073 47 441 (332-583) 2.63 (1.98-3.50) <0.0001
Down syndrome 536 15 280 (169-460) 1.66 (1.01-2.75) 0.05
Edward syndrome 95 4 433 (163-1099) 2.57 (0.98-6.72) 0.06
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others could not be explored. Due to the rarity of the out-
comes under examination, and the large number explored, we
did not perform classical hypothesis tests, as the division into
‘statistically significant’ and otherwise would have been poten-
tially misleading. To minimise any potential bias arising from
the incomplete capture of linked first and second pregnancies,
we restricted first pregnancies to 1985–2008 and second preg-
nancies to 1987–2010, providing aminimum of one complete
year between the first and the second delivery. This approach
should have improved the accuracy of our estimates at the ex-
pense of some precision, due to the small loss of sample size.
The most recent second pregnancies will have experienced
shorter postnatal follow-up periods than earlier births, poten-
tially resulting in lower rates of congenital anomaly. However,
more than 95% of major congenital anomalies are typically di-
agnosed either prenatally or within the first 2 years of life, and
even babies born at the end of 2010 will have been followed
for a minimum of 3 years, since our study includes notifica-
tions until the end of 2013. Regardless, we found no difference
in the RR of recurrence between pregnancies delivered during
1987–1998 and 1999–2010, suggesting that temporal factors,
such as improved diagnosis and ascertainment, are not related
to the mechanisms underlying the increased risk of recur-
rence. The RR of recurrence may be slightly overestimated, as
our denominator did not include late miscarriages, which
may be more common in women with a history of congenital
anomaly in a previous pregnancy. However, any such effect is
likely small, since the proportions of latemiscarriages in recur-
rent and non-recurrent groups are similarly rare, at around
1% of all observed deliveries.
Parity information was incomplete for around half of
the pregnancies complicated by congenital anomaly. To
minimise the risk of potential bias, we imputed parity
from maternal age, SEP, birth weight and year of deliv-
ery, all of which were correlated with parity in our sam-
ple. For comparison, we also estimated the ARs and RRs
of recurrence in those with complete parity information
using simple probability weights to correct for differ-
ences in the proportion of missing data between recur-
rent and non-recurrent second pregnancies. The
similarity of the estimates produced by these two ap-
proaches (within ± 3%) provides reassurance of the per-
formance of the imputation. Parity data were also
missing for the background population, so the propor-
tion of first and second pregnancies required estimation
from UK national trends, as did the number of second
pregnancies for women with a history of congenital
anomaly in the first pregnancy. Our estimate of the par-
ity distribution is likely to be very close to the true value,
as parity progression ratios are remarkably stable. For
every year between 1985 and 2000, for example, the
first-to-second pregnancy parity progression ratio for
England and Wales has varied from a low of 0.78 to a
high of 0.81 [27]. More recent data on the birth order
Table 2 Absolute and relative risk of recurrent congenital anomaly (of any group) in the second pregnancy, by congenital anomaly
group/subtype in the first pregnancy (Continued)
Klinefelter syndrome 26 2
Turner syndrome 97 4 413 (155-1055) 2.45 (0.93-6.44) 0.07
Genetic syndromes and microdeletions 332 31 933 (663-1299) 5.57 (3.97-7.81) <0.0001
DiGeorge syndrome 61 5 822 (343-1840) 4.88 (2.09-11.40) 0.0004
Stickler syndrome 7 3 4326 (1319-7928) 25.39 (10.14-63.58) <0.0001
Skeletal dysplasias 77 2
Osteogenesis imperfecta (type II) 28 2
Other syndromes, sequences, etc. 209 9 439 (230-823) 2.61 (1.37-4.95) 0.004
Laterality disturbance syndromesa 28 2
Noonan syndrome 14 2
Other genetic anomalies 36 6 1667 (761-3269) 9.89 (4.72-20.73) <0.0001
Ichthyosis 15 2
Neurofibromatosis 7 2
Multiple congenital anomalies 344 16 466 (287-748) 2.77 (1.71-4.48) 0.0001
Any congenital anomaly 7362 301 408 (365-456) 2.52 (2.25-2.83) <0.0001
Congenital anomaly groups (e.g. nervous system) and combined groups (i.e. isolated anomalies, syndromic anomalies and any congenital anomaly) are presented
in bold text, while congenital anomaly subtypes within the groups are presented in regular text
Counts, prevalence proportions and relative risks are the mean across ten multiply imputed datasets
Confidence intervals were derived from summary standard errors, which were combined using Rubin’s rule
Congenital anomaly groups and subtypes are classified in accordance with EUROCAT guidelines [24, 25]
The risks for groups and subtypes with at least three cases of recurrent pregnancies are reported
aIncludes Ivemark syndrome, left atrial isomerism and situs inversus
bEstimated second pregnancies during 1987–2010 in women with a first pregnancy during 1985–2008
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Table 4 Risk of recurrent congenital anomaly in the second pregnancy (from any group, from the same group, from a different
group) presented as natural frequency, by congenital anomaly group/subtype in the first pregnancy
Congenital anomaly group/subtype in
the first pregnancy
Risk, as natural frequency (95% CI)
Any congenital anomaly From the same group (similar) From a different group (dissimilar)
Isolated anomalies 1 in 28 (24-32) 1 in 58 (48-75) 1 in 54 (44-69)
Nervous system 1 in 25 (18-35) 1 in 53 (32-90) 1 in 47 (29-68b)
Neural tube defects 1 in 30 (19-49) 1 in 54 (28-103) 1 in 65a (33-65b)
Anencephaly 1 in 26 (13-52) 1 in 69 (23-215) 1 in 41 (17-63b)
Spina bifida 1 in 40 (18-61b) 1 in 60 (23-161)
Hydrocephalus 1 in 20 (9-47) 1 in 25 (10-62b)
Microcephaly 1 in 10 (5-25) 1 in 17 (6-54)
Cardiovascular 1 in 29 (23-36) 1 in 51 (38-68) 1 in 67a (48-92)
Ventricular septal defect (VSD) 1 in 25 (19-35) 1 in 42 (28-63) 1 in 64a (39-71b)
Atrial septal defect (ASD) 1 in 21 (11-41) 1 in 27 (13-61)
Pulmonary valve stenosis 1 in 49 (19-61b) 1 in 66 (22-205)
Aortic valve atresia/stenosis 1 in 33 (11-61b) 1 in 50 (13-201)
Coarctation of the aorta 1 in 30 (12-61b) 1 in 41 (13-127)
Orofacial clefts 1 in 28 (17-48) 1 in 50 (25-99) 1 in 64a (30-64b)
Cleft lip 1 in 26 (10-61b) 1 in 34 (12-62b)
Cleft lip and palate 1 in 26 (12-57) 1 in 31 (13-74)
Cleft palate 1 in 28 (12-61b) 1 in 47 (16-62b)
Digestive system 1 in 31 (18-54) 1 in 93 (35-246) 1 in 46 (23-64b)
Diaphragmatic hernia 1 in 16 (7-38) 1 in 26 (9-62b)
Abdominal wall 1 in 61a (24-61b) 1 in 62a (28-62b)
Gastroschisis 1 in 57 (19-61b) 1 in 62a (22-62b)
Urinary 1 in 22 (16-31) 1 in 47 (29-76) 1 in 42 (26-66b)
Cystic kidney disease 1 in 18 (9-36) 1 in 29 (12-70) 1 in 48 (16-63b)
Limb 1 in 49 (21-61b) 1 in 61a (23-62b)
Polydactyly 1 in 14 (4-55) 1 in 14 (4-55)
Musculoskeletal 1 in 12 (5-31) 1 in 12 (5-31)
Syndromic anomalies 1 in 19 (15-22) 1 in 35 (28-48) 1 in 40 (31-55)
Chromosomal syndromes 1 in 23 (17-30) 1 in 37 (26-53) 1 in 59 (37-75b)
Down syndrome 1 in 36 (22-59) 1 in 77 (37-160) 1 in 67a (34-67b)
Edward syndrome 1 in 23 (9-61)
Turner syndrome 1 in 24 (9-61b)
Genetic syndromes and microdeletions 1 in 11 (8-15) 1 in 18 (12-29) 1 in 26 (15-44)
DiGeorge syndrome 1 in 12 (5-29) 1 in 15 (6-40)
Stickler syndrome 1 in 2 (1-8) 1 in 2 (1-8)
Other syndromes, sequences, etc. 1 in 23 (12-43) 1 in 70 (23-216) 1 in 34 (16-63b)
Other genetic anomalies 1 in 6 (3-13) 1 in 7 (3-17)
Multiple congenital anomalies 1 in 21 (13-35) 1 in 25 (15-41)
Any congenital anomaly 1 in 24 (22-27) 1 in 49 (42-59) 1 in 49 (42-59)
Congenital anomaly groups (e.g. nervous system) and combined groups (i.e. isolated anomalies, syndromic anomalies and any congenital anomaly) are presented
in bold text, while congenital anomaly subtypes within the groups are presented in regular text
aEstimate truncated at baseline risk
bConfidence limit truncated at baseline risk
Only those groups and subtypes with at least three cases of recurrent pregnancies are reported
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distribution in England and Wales suggest that this has
remained equally static (exactly 0.79 in 2009, 2010 and
2011) [29]. Although parity progression ratios do vary by
maternal age and SEP, which may lead to some regional
variation, the effect sizes are modest, and any divergence
from the national profile is therefore likely to be modest
[30]. In the absence of conflicting evidence, we assumed
that women whose first pregnancy was affected by congeni-
tal anomaly had the same probability of second pregnancy
as the general population, but experience of congenital
anomaly is plausibly associated with altered reproductive
health and/or behaviour. In a Dutch sample of parents who
experienced termination of pregnancy for congenital anom-
aly, 6% of mothers and 9% of fathers indicated they ‘would
refrain from a next pregnancy for fear of another anomal-
ous child’ [31]. If we recalculate our RR for recurrence
using a similar 9% decrease in the probability of a subse-
quent pregnancy, it increases to 2.78 (95% CI 2.47–3.12).
Similarly, using an even smaller probability of parity pro-
gression, like the 68% observed in Norway during 1967–
1989 after a first pregnancy affected by congenital anomaly
[16], increases the RR further; in this instance to 2.99 (95%
CI 2.66–3.36). For our RR to be an overestimate of the true
RR, experience of congenital anomaly in the first pregnancy
would need to be associated with a higher probability of
subsequent pregnancy. The RR plateaus at 2.00 (1.78–2.25)
if 100% of such women are assumed to have had a second
pregnancy. It is hence unlikely that the results or implica-
tions of our study are materially biased by the use of an es-
timated parity progression ratio.
Our finding of a lower prevalence of congenital anom-
alies in the second pregnancy compared with the first
pregnancy agrees with a previous study suggesting that
nulliparity is associated with a higher risk of specific
congenital anomalies [32]. There are few population-
based studies exploring recurrence risk of unselected
congenital anomalies in singleton siblings. Previous stud-
ies from Scandinavia [15, 16] and the USA [17] re-
stricted their analysis of recurrence risk to first and
second births to avoid issues related to selective fertility
[33]. We followed a similar approach. The summary RR
of recurrence estimated in our study (RR = 2.5) is com-
parable with that reported in the Norwegian study [16]
(RR = 2.4) and slightly higher than that in the US [17]
(RR = 1.9) and in the Danish [15] (RR = 1.8) studies. The
summary RR for similar anomalies was higher in our
study (23.7-fold) than in any of these studies: RR = 11.7,
RR = 7.6 and OR = 5.4 in the US [17], Norwegian [16]
and Danish [15] studies respectively. This likely results
from better ascertainment and our use of the EUROCAT
classification system, which includes much more homo-
geneous groupings. For dissimilar anomalies, the RR was
similarly low across all studies, including ours, ranging
between 1.2 and 1.5. Between-study comparisons of
specific anomaly groups are particularly hindered by dif-
ferences in classification and inclusion criteria. In many
of the earlier studies, for example, chromosomal syn-
dromes were combined with other syndromes, yet we
found heterogeneity between these groups. These issues
preclude detailed comparison with an older and much
smaller UK study, which used data from the Birming-
ham Malformation Register for 1964–1984 [34]; the
overall RRs of 17.8 and 1.8 for similar and dissimilar
anomalies respectively are however remarkably similar.
In summary, our study has a number of strengths over
all existing population-based studies which were pub-
lished in the 1990s and hence used old classification
schemes of congenital anomalies, applied inconsistent
inclusion criteria (including minor anomalies) and
lacked detail, particularly with respect to absolute risks,
for many specific congenital anomaly groups and sub-
types. Our risk estimates are generalizable to other re-
gions of the UK and Europe.
The causes of some congenital anomalies (e.g. single
gene defects, chromosomal anomalies, specified syn-
dromes) are known, and the recurrence risks can be
estimated accordingly. However, for about 70% of non-
syndromic structural anomalies (e.g. cardiovascular
anomalies, neural tube defects and orofacial clefts), the
causes are still unknown and are thought to consist of a
multifactorial combination of genetic factors, environ-
mental factors and gene-environment interaction [3, 35,
36]. Some genetic variants, both common and rare, have
been implicated in the risk of non-syndromic congenital
anomalies [36]. Polymorphisms in the folate-related gene
MTHFR, for example, have been shown to increase the
risk of neural tube defects [36]. For similar anomalies in
the second pregnancy, we estimated 12.4-fold, 3.6-fold
and 32.3-fold increased recurrence risks for nervous sys-
tem anomalies (including neural tube defects), cardio-
vascular anomalies and orofacial clefts respectively.
These are many times greater than the effect of most
recognised environmental teratogens, suggesting that a
specific mechanism, such as a genetic or epigenetic
exposure, may be involved — especially given the
consistency in the estimated RRs across different studies.
Repeated environmental exposures such as maternal dia-
betes, maternal obesity and micronutrient deficiencies,
are however also likely to contribute to the risk of recur-
rence. We found that women from more deprived SEPs
experienced a higher risk of recurrent congenital anom-
aly in the second pregnancy than those from more
advantaged SEPs, although the effect was attenuated by
adjustment for maternal age. Younger maternal age is
strongly correlated with a more deprived SEP, which
likely explains the dilution of the area-based measure.
Potential explanations for the higher risk of recurrence
in younger women include various behaviour risk factors
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such as smoking, recreational drug use, alcohol con-
sumption and unplanned pregnancy, none of which
could be controlled for in our study. Similarly, the reli-
ance on routinely collected data meant we were unable
to explore other potential modifiers of the risk of recur-
rence, such as a change in partner and/or residence be-
tween pregnancies.
Conclusions
This study provides detailed information on the ARs and
RRs of recurrence of congenital anomaly for several spe-
cific (and well-defined) groups and subtypes for women
whose first pregnancies were complicated by congenital
anomaly. This should prove extremely useful during pre-
conception counselling of mothers and their families
when considering subsequent pregnancies and during
antenatal or postnatal counselling to support decision
making and — in many cases — provide reassurance
[13]. Although the relative risks of recurrence were
alarmingly high for many groups and subtypes – particu-
larly for similar anomalies where unidentified genetic
factors may be involved – the absolute risks, in the vast
majority of instances, are relatively low. For structural
anomalies, like neural tube defects, these could be fur-
ther reduced by help with planning and preparation for
pregnancy, particularly in higher risk groups such as
women with diabetes [37]. Furthermore, many potential
pre-pregnancy interventions, such as maternal and pa-
ternal [36] periconception folate supplementation, re-
view of current medication and help and advice with
diet and physical activity during preparation for next
pregnancy, are likely to reduce the risk of other adverse
pregnancy outcomes, including congenital anomalies.
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